Evidence map›Paper›PMID 35434592›Full record

ArticleJournal of translational autoimmunity2022

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases.

Regina Larionova, K Byvaltsev, Оlga Kravtsova, Elena Takha, Sergei Petrov, Gevorg Kazarian, Anna Valeeva, Eduard Shuralev, Malik Mukminov, Yves Renaudineau and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational autoimmunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Regina LarionovaCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
K ByvaltsevInstitute of Fundamental Medicine, Kazan (Volga Region) Federal University, Kazan, Russia.
Оlga KravtsovaInstitute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan, Russia.
Elena TakhaCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Sergei PetrovCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Gevorg KazarianCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Anna ValeevaCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Eduard ShuralevCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Malik MukminovCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Yves RenaudineauCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Marina ArleevskayaCentral Research Laboratory, Kazan State Medical Academy, Kazan, Russia.
Kazan State Medical Academy · RUKazan Federal University · RUA.E. Arbuzov Institute of Organic and Physical Chemistry · RUCentre Hospitalier Universitaire de Toulouse · FRKazan State Academy of Veterinary Medicine named after N.E. Bauman · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical and immunological spectrum of acute and post-active COVID-19 syndrome overlaps with criteria used to characterize autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Indeed, following SARS-Cov2 infection, the innate immune response is altered with an initial delayed production of interferon type I (IFN-I), while the NF-kappa B and inflammasome pathways are activated. In lung and digestive tissues, an alternative and extrafollicular immune response against SARS-Cov2 takes place with, consequently, an altered humoral and memory T cell response leading to breakdown of tolerance with the emergence of autoantibodies. However, the risk of developing severe COVID-19 among SLE and RA patients did not exceed the general population except in those having pre-existing neutralizing autoantibodies against IFN-I. Treatment discontinuation rather than COVID-19 infection or vaccination increases the risk of developing flares. Last but not least, a limited number of case reports of individuals having developed SLE or RA following COVID-19 infection/vaccination have been reported. Altogether, the SARS-Cov2 pandemic represents an unique opportunity to investigate the dangerous interplay between the immune response against infectious agents and autoimmunity, and to better understand the triggering role of infection as a risk factor in autoimmune and chronic inflammatory disease development.

Indexed as

ACE2, angiotensin converting enzyme 2ACPA, anti-cyclic citrullinated peptide autoAbANA, antinuclear autoAbaPL, antiphospholipidAutoAb, autoantibodiesBAFF/BlySS, B-cell-activating factor/B lymphocyte stimulatorCCL, chemokine ligandCOVID-19, coronavirus disease 2019DMARDs, disease-modifying anti-rheumatic drugsE, envelopeHEp-2, human epithelioma cell line 2IFNAR, IFN-alpha receptorsIFN-I, interferon type IIg, immunoglobulinIL, interleukinInfectionInflammationIRF, interferon regulatory factorISGs, IFN-stimulated genesITP, immune-thrombocytopenic purpuraJak, Janus kinaseLDH, lactate dehydrogenasemAb, monoclonal AbMDA-5, melanoma differentiation-associated proteinMERS-Cov, Middle East respiratory syndrome coronavirusMIS-C, multisystem inflammatory syndrome in childrenM, membraneNET, nuclear extracellular trapsNF-κB, nuclear factor-kappa BNK, natural killerNLRP3, NOD-like receptor familyN, nucleocapsidopen reading frame, PACSpathogen-associated molecular patterns, pDCpattern recognition receptors, RApeptidylarginine deiminase 4, PAMPsplasmacytoid dendritic cells, PMNpolymorphonuclear leukocytes, PRRspost-active COVID-19 syndrome, PAD-4primary Sjögren's syndrome, SLEpyrin domain containing 3, ORFreactive oxygen species, rt-PCRreceptor binding domain, RFregulatory T cells, VDJretinoic acid-inducible gene I, ROSreverse transcription polymerase chain reaction, SRheumatoid arthritisrheumatoid arthritis, RBDrheumatoid factor, RIG-IRisk factorsSARS-Cov2severe acute respiratory coronavirus 2, SjSsignal transducer and activator of transcription, TCRsingle-stranded ribonucleic acid, STATspike, SADsystemic autoimmune disease, SARS-Cov2Systemic lupus erythematosussystemic lupus erythematosus, SScsystemic sclerosis, ssRNAT cell receptor, TLRToll-like receptor, TMPRSS2transmembrane serine protease 2, TNFtumor necrosis factor, Tregvariable, diversity and joining Ig genes

Identifiers

PMID35434592
PMCPMC9005220
OpenAlexW4223584860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.